Nonablative allogeneic stem-cell transplantation for advanced/recurrent XXXX .

@entity1 @entity900 @entity786 @entity2592 @entity3118 @entity2132 @entity1073 @entity1140 @entity1499
PURPOSE: @entity1 with relapsed @entity1073 have poor prognosis and short survival. Our aim was to determine the efficacy of nonablative allogeneic stem-cell transplantation in @entity1 with relapsed @entity1073 . @entity1 AND METHODS: Eighteen @entity1 were treated in one of two consecutive trials. Thirteen @entity1 underwent a conditioning regimen of @entity3118 (30 mg/m2 daily for 3 days), @entity786 (750 mg/m2 daily for 3 days), and high-dose rituximab. For the remaining five @entity1 , the conditioning regimen consisted of @entity900 (25 mg/m2 daily for 4 days), @entity3118 (30 mg/m2 daily for 2 days), and @entity2592 (1,000 mg/m2 daily for 2 days). @entity1140 and @entity1499 were used for graft-versus-host disease prophylaxis. RESULTS: The median age was 56.5 years. @entity1 underwent a median of three prior chemotherapy regimens. Prior autologous transplantation failed in five (28%) @entity1 and 16 (89%) had chemosensitive disease. Donor cell engraftment occurred in all @entity1 . Eight @entity1 (44%) required no platelet or RBC transfusion, and @entity2132 of greater than grade 2 did not develop in any @entity1 . The day-100 mortality was 0%. Complete remission (CR) occurred in 17 @entity1 . Three @entity1 progressed, and one was reinduced into continuous CR with donor lymphocyte infusion. With a median follow-up period of 26 months, the actuarial probability of current-event-free-survival at 3 years was 82% (95% CI, 65% to 99%). CONCLUSION: Our data suggest that nonablative allogeneic transplantation is a safe and potentially effective strategy for @entity1 with relapsed and chemosensitive @entity1073 .
